(Boursier.com) — Neovacs a biopharmaceutical company at a preclinical stage developing new therapies for inflammatory and autoimmune diseases, announces the entry into national phases of its patent relating to its mRNA vaccine candidates in the field of allergies.
As a reminder, an mRNA vaccine candidate directed against the cytokines IL-4 and IL-13 is being developed by Néovacs for the treatment of allergies. The concept was validated by the production of neutralizing antibodies in humanized mouse models. The immune response and tolerance to the vaccine are currently being evaluated in non-human primates under ‘R&D’ conditions, with results expected at the start of the second quarter of 2024.
This IL-4 and IL-13 mRNA vaccine candidate is protected by an international patent filed in August 2021 entitled “mRNA vaccines comprising IL4 and/or IL13 RNA and uses thereof”.
The invention claims the use of a therapeutic vaccine as a treatment for pathological effects associated with overexpression of IL-4 and IL-13, particularly in asthma, food allergies, responses to venoms and the occurrence anaphylactic shock, atopic dermatitis, pulmonary fibrosis and chronic obstructive pulmonary disease (COPD).
The patent is entering the examination phase by the offices of the States in which grant is desired, namely 10 countries in Europe, America, Asia and 4 other associated territories, including in particular the United States, China and Japan.
©2024 Boursier.com